Compare WTW & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTW | ONC |
|---|---|---|
| Founded | 1828 | 2010 |
| Country | United Kingdom | Switzerland |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.8B | 34.8B |
| IPO Year | N/A | N/A |
| Metric | WTW | ONC |
|---|---|---|
| Price | $321.25 | $321.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | ★ $369.75 | $369.50 |
| AVG Volume (30 Days) | ★ 640.3K | 332.1K |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.15% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 21.32 | 0.58 |
| Revenue | ★ $9,807,000,000.00 | $4,972,687,000.00 |
| Revenue This Year | N/A | $36.37 |
| Revenue Next Year | $6.05 | $22.04 |
| P/E Ratio | ★ $15.04 | $553.50 |
| Revenue Growth | N/A | ★ 53.47 |
| 52 Week Low | $292.97 | $170.99 |
| 52 Week High | $352.79 | $385.22 |
| Indicator | WTW | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 48.92 | 42.54 |
| Support Level | $314.48 | $325.00 |
| Resistance Level | $324.43 | $340.98 |
| Average True Range (ATR) | 4.84 | 13.32 |
| MACD | 0.61 | -3.46 |
| Stochastic Oscillator | 63.37 | 16.88 |
Willis Towers Watson PLC is an advisory, broking, and solutions company that provides data-driven, insight-led solutions in the areas of people, risk, and capital. The company's segments include Health, Wealth & Career (HWC) and Risk & Broking (R&B). The HWC segment provides an array of advice, broking, solutions and technology for employee benefit plans, institutional investors, compensation and career programs, and employee experience overall. It focuses on four key areas: Health, Wealth, Career and Benefits Delivery & Outsourcing. The R&B segment provides risk advice, insurance brokerage and consulting services to clients ranging from small businesses to multinational corporations. Its R&B segment includes two businesses: Corporate Risk & Broking and Insurance Consulting and Technology.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.